JOINT CORP — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
JOINT CORP — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 5.10% | -5.50% | 6.00% | 27.50% | -5.00% | 56.10% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | — | — | 3.10% | 0.10% | 2.40% | 20.80% |
| SBC (Nondeductible) | — | — | — | — | 7.40% | 12.30% |
| Nondeductible Expenses | — | — | — | — | — | — |
| Valuation Allowance Change | -1.64% | 1.20% | 0.00% | 42.09% | -4.10% | 2.21% |
| Tax Law Change | — | -0.20% | -9.30% | 67.30% | -7.70% | — |
| Effective Tax Rate | -143.30% | -24.90% | 9.80% | 43.40% | -0.30% | -16.80% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$7.8M | −$1.5M | $5.6K | $11.0M | $5.6K | $38.7K |
| Income Taxes Paid (Cash) | — | $566.8K | — | $569.8K | $610.5K | $626.8K |
JOINT CORP — Litigation CasesNEW
Per-case litigation disclosures sourced from us-gaap:LossContingenciesByNatureOfContingencyAxis dimensional XBRL. Coverage is sparse — most filers aggregate at the parent level (JNJ talc, PFE opioid) — but high-value when per-case disclosure exists. Loss estimate is either a single point or a low/high range, depending on how the issuer values the contingency.
As of 2025-02-25
| Case | Estimated Loss | Damages Sought | Settlement |
|---|---|---|---|
| Medical Injury Claim | — | — | $3M |
| Employment Matters | — | — | $2M |